COPD Clinical Trial
Official title:
Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation
| NCT number | NCT01799330 |
| Other study ID # | 0809004250 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | December 2008 |
| Est. completion date | May 8, 2014 |
| Verified date | September 2020 |
| Source | Yale University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The two hypotheses to be tested in this study are that:
1. The administration of transcutaneous electrical muscle stimulation (TCEMS) after
completion of conventional exercise training in pulmonary rehabilitation (PR) will
result in further improvements in exercise tolerance, functional status and symptoms of
patients with stable chronic obstructive pulmonary disease (COPD) above those achieved
in PR alone.
2. TCEMS can improve exercise tolerance, functional status and symptoms even among COPD
patients who fail to make gains in exercise tolerance by participating in conventional
PR due to their debilitation and/or marked cardio-respiratory impairment.
| Status | Completed |
| Enrollment | 32 |
| Est. completion date | May 8, 2014 |
| Est. primary completion date | May 8, 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A to 75 Years |
| Eligibility |
Inclusion Criteria: Pulmonary function test criteria consistent with a diagnosis of COPD including forced expiratory volume in one second (FEV1) < 65% of predicted, with FEV1/FVC (forced vital capacity) ratio < 70%, lung hyperinflation based on a residual volume to total lung capacity (RV/TLC) ratio > 120% predicted and reduced diffusing capacity for carbon monoxide (DLCO <70% predicted). Self-reported exercise limitation despite pharmacologic treatment. Otherwise medically stable. Women and minorities will also be recruited. Only persons able to give fully informed consent will be enrolled in the study. Exclusion Criteria: Patients will be excluded from study participation if they have a history of uncontrolled cardiovascular disease (including ventricular arrhythmia, myocardial infarction within 1 year, unstable angina, cardiac pacemaker or other implanted electrical device, other uncontrolled arrhythmias, or unstable blood pressure), neuromuscular disease (including stroke), debilitating joint disease or amputations that precludes exercise or have other contraindications to participating in outpatient PR (including unstable bone fracture, syncope of unclear etiology or cancer undergoing active chemotherapy), or are pregnant. Persons with a history of seizure disorder, intracranial clips or skin problems that would prevent safe or proper placement of the electrodes needed for electrical stimulation of the leg muscles will be excluded, based on prior clinical studies of TCEMS in non-COPD populations. Patients will also be excluded from study participation if they have undergone formal PR within 1 year of the date of study inclusion. No patients will be recruited from a "vulnerable patient population", including economically or educationally disadvantaged or mentally disabled persons, children, or prisoners. |
| Country | Name | City | State |
|---|---|---|---|
| United States | VA Connecticut Healthcare System | West Haven | Connecticut |
| Lead Sponsor | Collaborator |
|---|---|
| Yale University | VA Connecticut Healthcare System |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incremental Shuttle Walk Test (SWT) | The incremental Shuttle Walk Test will be used as a measure of exercise capacity. This test measures the maximal distance walked by the patient around two position markers set 10 meters apart, at a pace set by audio signals from a cassette tape. Minute-by-minute walking speed is increased until the patient feels too tired or short of breath to continue, or is unable to walk at least half of the 10 meter distance by the time the next audio signal is heard. Patients who routinely use supplemental oxygen will perform the test while carrying their portable oxygen delivery system during testing. As noted above, a practice run will be performed on the day the patient comes in for familiarization with the protocol and equipment. The investigator conducting the Shuttle Walk Test will be blinded to the groupings of subjects to avoid potential bias of the results. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Body Composition | Body composition will be assessed using bioelectrical impedance analysis (Hydra 4200; Xitron Technologies, San Diego, CA) at a standardized time after breakfast. Bioelectrical impedance analysis (BIA) is a simple, safe, non-invasive method to measure assess lean (e.g., muscle) vs. fat body compartments. Fat-free mass will be calculated by using disease-specific equations as described by Schols. Fat mass will then be calculated as total body weight minus fat-free mass. Such BIA measurements are accurate, comparable to other techniques used to assess body composition, and have been validated in patients with COPD. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Body Mass Index (BMI) | BMI is calculated as weight in kg/height in m2. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Pulmonary Function | Spirometry, lung volume and diffusing capacity measurements will be performed according to standard procedure in the pulmonary function laboratory by a trained pulmonary function technician at either the Newington or West Haven Campus of VACHS according to American Thoracic Society Guidelines. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Muscle Strength | Quadriceps and hamstring muscle maximal isokinetic strengths will be measured with the patient in an upright seated position, at an angular velocity of 60 degree/sec using a Biodex Multijoint System 2 dynamometer. Five duplicate leg extension and flexion measurements from a resting knee joint angle of 90 degrees will be made with adequate rest periods (2 min) in between efforts. The best peak torque value in Newton-meter (Nm) unit will be recorded. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Six Minute Walk Test (6MWT) and Borg Dyspnea Rating | The total distance walked in 6 minutes is recorded. The 6 minute walk test is well validated for use and is used widely in pulmonary rehabilitation programs, as it is sensitive to changes in exercise endurance that occur following exercise training. The degree of perceived exertion will be assessed at the end of the 6MWT using a Borg Dyspnea scale (a patient-reported numerical rating of the degree of dyspnea associated with any given degree of exertion). | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Cardiopulmonary Exercise Test | Maximal symptom-limited incremental cardiopulmonary exercise testing (CPET) will be performed by a pulmonary function/exercise technologist according to standard methods used in the West Haven VA Pulmonary Function Laboratory, using a calibrated cycle ergometer (Collins Gold Standard Plus Cardiopulmonary Exercise System, Pulmonary Data Services, Louisville, CO) with a pedaling frequency of 40 revolutions per minute, during which the workload will increase by 5-20 Watt increments every minute depending on the subjects' exercise capacity. Breathing rate, tidal volume, minute ventilation, and electrocardiography will be measured continuously according to standard procedure. Oxygen consumption and carbon dioxide production will be calculated from the fractional concentrations of oxygen and carbon dioxide in the mixed expired gas using a Collins CPX Unit metabolic system (Pulmonary Data Services, Louisville, CO). | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Dyspnea Scale | The Medical Research Council Dyspnea Scale is a simple questionnaire in which the patient rates the level of exertion/activity at which he/she experiences dyspnea, by checking one of five boxes on a five point scale. This questionnaire takes approximately 5 minutes to complete. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Chronic Respiratory Disease Questionnaire | The Chronic Respiratory Disease Questionnaire is a respiratory-specific health status instrument in which patients give responses to simple questions encompassing four principal domains: dyspnea, fatigue, emotion and mastery. This questionnaire is used routinely worldwide as a health status outcomes measure in pulmonary rehabilitation programs, including the outpatient PR program at the West Haven VA, as it is highly responsive to the PR intervention. Total and the four sub-scores for each of the domains tested will be analyzed. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS | |
| Secondary | Medical Outcome Survey Short-Form-36 (SF-36) Questionnaire | The SF-36 is a general health status questionnaire in which patients give responses to questions encompassing domains of physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Physical and mental summary scores can be calculated from these subscales. | Baseline, Post 8 Weeks PR, Post 8 Weeks Active/Sham TCEMS |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
| Completed |
NCT04105075 -
COPD in Obese Patients
|
||
| Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
| Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
| Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
| Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
| Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
| Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
| Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
| Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
| Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
| Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
| Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
| Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
| Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |